N05BA09

Long-acting benzodiazepine indicated in It is used in the treatment of epilepsy and anxiety disorders. Oral administration once a day.

According to an study from 1978, it is excreted in breastmilk in small amounts, but which could be significant. ^{(Schaefer 2007 p728, Bennett 1996 p 409)}

A 25-day-old infant whose mother was taking clobazam and levetiracetam presented sedation, vomiting and weight loss ^{(Paret 2014}). No adverse effects were reported in a newborn whose mother was taking tiagabine, clobazam and oxcarbazepine daily. ^{(Tomson 2007)}

It is advisable to monitor drowsiness and the adequate feeding of the infant during maternal treatment with clobazam. ^{(Bar-Oz 2012)}

In general, occasional and low dose use of benzodiazepines is compatible with breastfeeding. ^{(Kelly 2012, Rubin 2004, Iqbal 2002, Hägg 2000, McElhatton 1994, Lee 1993, Bennet 1996, Kanto 1982)}

It is advisable to choose short-acting benzodiazepines and use the minimum effective dose ^{(Rowe 2013)}, especially during the neonatal period and in cases of prematurity because they can accumulate in the infant during chronic use. ^{(Sachs 2013)}

It is advisable to monitor drowsiness and the adequate feeding of the infant. It is not recommended to share a bed with the baby if this medication is being taken due to an increased risk of suffocation or sudden infant death^{. (ABM 2020, UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006)}

See below the information of this related product:

• Maternal Epilepsy (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)